Therapy Trends: Rheumatoid Arthritis -- Consensus Outlook Module
Analyse the latest global RA market players and products, and start mapping your future market parameters with Therapy Trends’ Consensus Outlook: Rheumatoid Arthritis, which includes the following comprehensive resources:
Consensus Outlook: Rheumatoid Arthritis is a data analysis module compiled from meticulous FirstWord research. Its historical sales data (2006–11) is based on company information. The five-year (2012-16) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.
This Consensus Outlook collates and evaluates the latest relevant reports and forecasts published by leading equity research analysts. This information is fed into the Therapy Trends Forecast model to give unbiased consensus forecasts.
Overall, this module offers you independent, unbiased, accurate forecasts from leading financial institutions with the most intimate commercial knowledge of the competitive players and products in this disease sector.
Forecast Spreadsheets
Save valuable time by focusing on FirstWord’s 5-year RA forecast data with our detailed Excel spreadsheets. Consensus Outlook: Rheumatoid Arthritis allows you to quickly compare various market parameters by:
Stay one step ahead of your competition with FirstWord’s Consensus Outlook updates. Receive these directly over the next 12 months, following major RA market events, within days of each event’s occurrence.
Consensus Outlook Benefits:
- An in-depth 5-year forecast report based on analyst consensus
- Detailed data spreadsheets comparing critical market parameters
- Regular updates over the next 12 months, after major market events
- Historical RA sales from 2006–2011
- Forecast RA sales from 2012-2016
- Key competitors and drug developers
- Predicted product positioning
- Current and late-stage pipeline drugs
- Future event mapping to forecast data points
- Comparative clinical trial results
Consensus Outlook: Rheumatoid Arthritis is a data analysis module compiled from meticulous FirstWord research. Its historical sales data (2006–11) is based on company information. The five-year (2012-16) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.
This Consensus Outlook collates and evaluates the latest relevant reports and forecasts published by leading equity research analysts. This information is fed into the Therapy Trends Forecast model to give unbiased consensus forecasts.
Overall, this module offers you independent, unbiased, accurate forecasts from leading financial institutions with the most intimate commercial knowledge of the competitive players and products in this disease sector.
Forecast Spreadsheets
Save valuable time by focusing on FirstWord’s 5-year RA forecast data with our detailed Excel spreadsheets. Consensus Outlook: Rheumatoid Arthritis allows you to quickly compare various market parameters by:
- Market size
- International and US markets
- Product sales
- Brand, company and drug class
- Company forecasts
- Mechanism of action
Stay one step ahead of your competition with FirstWord’s Consensus Outlook updates. Receive these directly over the next 12 months, following major RA market events, within days of each event’s occurrence.
Consensus Outlook Benefits:
- Chart predicted market growth and product sales
- Map your own market parameters
- Tailor your strategic and investment focus
- Assess your current and future sales resources
- Set proactive launches and branding strategies
CONSENSUS OUTLOOK
INTERACTIVE DATA ANALYSIS FILE (EXCEL)
TABS:
Market size
Product sales
Company forecast
Mechanism of action
Events
MARKET ANALYSIS FILE (PDF)
CONTENTS:
FirstWord Analysis Highlights
Rheumatoid Arthritis marketplace
Key Rheumatoid Arthritis developers
Rheumatoid arthritis class dynamics
Enbrel (etanercept; Amgen/Pfizer/Takeda) forecast
Humira (adalimumab; Abbott/Eisai) forecast
Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) forecast
Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./ Mitsubishi Tanabe) forecast
Cimzia (certolizumab; UCB) forecast
Orencia (abatacept; Bristol-Myers Squibb) forecast
Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai) forecast
Actemra/RoActemra (tocilizumab; Chugai/Roche) forecast
Tofacitinib (CP-690,550; Pfizer/Takeda) forecast
Fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals) forecast
Secukinumab (AIN457; Novartis) forecast
INTERACTIVE DATA ANALYSIS FILE (EXCEL)
TABS:
Market size
Product sales
Company forecast
Mechanism of action
Events
MARKET ANALYSIS FILE (PDF)
CONTENTS:
FirstWord Analysis Highlights
Rheumatoid Arthritis marketplace
Key Rheumatoid Arthritis developers
Rheumatoid arthritis class dynamics
Enbrel (etanercept; Amgen/Pfizer/Takeda) forecast
Humira (adalimumab; Abbott/Eisai) forecast
Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) forecast
Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./ Mitsubishi Tanabe) forecast
Cimzia (certolizumab; UCB) forecast
Orencia (abatacept; Bristol-Myers Squibb) forecast
Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai) forecast
Actemra/RoActemra (tocilizumab; Chugai/Roche) forecast
Tofacitinib (CP-690,550; Pfizer/Takeda) forecast
Fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals) forecast
Secukinumab (AIN457; Novartis) forecast
FIGURES:
Rheumatoid Arthritis worldwide market sales value, 2006–2016
Growth and market share of the US and international RA markets, 2006–16
Rheumatoid Arthritis worldwide market sales value, 2006–2016
Rheumatoid Arthritis worldwide market share difference from 2006 to 2016
Rheumatoid Arthritis worldwide market sales value split by class, 2011
Sales dynamics of leading Alzheimer’s disease brands, 2011-2016
Sales dynamics of Enbrel (etanercept; Amgen/Pfizer/Takeda), 2006-2016
Enbrel (etanercept; Amgen/Pfizer/Takeda) sales by region worldwide ($m), 2006–2016
Sales dynamics of Humira (adalimumab; Abbott/Eisai), 2006-2016
Humira (adalimumab; Abbott/Eisai) sales by region worldwide ($m), 2006–2016
Sales dynamics of Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe), 2006-2016
Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) sales by region worldwide ($m), 2006–2016
Sales dynamics of Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe), 2009-2016
Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) sales by region worldwide ($m), 2009–2016
Sales dynamics of Cimzia (certolizumab; UCB), 2009-2016
Cimzia (certolizumab; UCB) sales by region worldwide ($m), 2009–2016
Sales dynamics of Orencia (abatacept; Bristol-Myers Squibb), 2006-2016
Orencia (abatacept; Bristol-Myers Squibb) sales by region worldwide ($m), 2009–2016
Sales dynamics of Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai), 2006-2016
Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai) sales by region worldwide ($m), 2009–2016
Sales dynamics of Actemra/RoActemra (tocilizumab; Chugai/Roche), 2006-2016
Actemra/RoActemra (tocilizumab; Chugai/Roche) sales by region worldwide ($m), 2009–2016
Sales dynamics of tofacitinib (CP-690,550; Pfizer/Takeda), 2012-2016
Tofacitinib (CP-690,550; Pfizer/Takeda) sales by region worldwide ($m), 2012–2016
Sales dynamics of fostamatinib disodium (R788), 2011-2016
Sales dynamics of fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals), 2014-2016
Sales dynamics of secukinumab (AIN457; Novartis), 2014-2016
Secukinumab (AIN457; Novartis) sales by region worldwide ($m), 2014–2016
Rheumatoid Arthritis worldwide market sales value, 2006–2016
Growth and market share of the US and international RA markets, 2006–16
Rheumatoid Arthritis worldwide market sales value, 2006–2016
Rheumatoid Arthritis worldwide market share difference from 2006 to 2016
Rheumatoid Arthritis worldwide market sales value split by class, 2011
Sales dynamics of leading Alzheimer’s disease brands, 2011-2016
Sales dynamics of Enbrel (etanercept; Amgen/Pfizer/Takeda), 2006-2016
Enbrel (etanercept; Amgen/Pfizer/Takeda) sales by region worldwide ($m), 2006–2016
Sales dynamics of Humira (adalimumab; Abbott/Eisai), 2006-2016
Humira (adalimumab; Abbott/Eisai) sales by region worldwide ($m), 2006–2016
Sales dynamics of Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe), 2006-2016
Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) sales by region worldwide ($m), 2006–2016
Sales dynamics of Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe), 2009-2016
Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) sales by region worldwide ($m), 2009–2016
Sales dynamics of Cimzia (certolizumab; UCB), 2009-2016
Cimzia (certolizumab; UCB) sales by region worldwide ($m), 2009–2016
Sales dynamics of Orencia (abatacept; Bristol-Myers Squibb), 2006-2016
Orencia (abatacept; Bristol-Myers Squibb) sales by region worldwide ($m), 2009–2016
Sales dynamics of Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai), 2006-2016
Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai) sales by region worldwide ($m), 2009–2016
Sales dynamics of Actemra/RoActemra (tocilizumab; Chugai/Roche), 2006-2016
Actemra/RoActemra (tocilizumab; Chugai/Roche) sales by region worldwide ($m), 2009–2016
Sales dynamics of tofacitinib (CP-690,550; Pfizer/Takeda), 2012-2016
Tofacitinib (CP-690,550; Pfizer/Takeda) sales by region worldwide ($m), 2012–2016
Sales dynamics of fostamatinib disodium (R788), 2011-2016
Sales dynamics of fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals), 2014-2016
Sales dynamics of secukinumab (AIN457; Novartis), 2014-2016
Secukinumab (AIN457; Novartis) sales by region worldwide ($m), 2014–2016
TABLES:
Sales and growth of regions for Rheumatoid Arthritis, 2011–2016
Leading companies in the branded worldwide Rheumatoid Arthritis market, 2011–2016
Sales and growth of classes in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the global revenues of Enbrel (etanercept; Amgen/Pfizer/Takeda) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the global revenues of Humira (adalimumab; Abbott/Eisai) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the global revenues of Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the global revenues of Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of Cimzia (certolizumab; UCB) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of Orencia (abatacept; Bristol-Myers Squibb) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of Actemra (tocilizumab) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of tofacitinib (CP-690,550; Pfizer/Takeda) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of secukinumab (AIN457; Novartis) in Rheumatoid Arthritis, 2014–2016
Sales and growth of regions for Rheumatoid Arthritis, 2011–2016
Leading companies in the branded worldwide Rheumatoid Arthritis market, 2011–2016
Sales and growth of classes in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the global revenues of Enbrel (etanercept; Amgen/Pfizer/Takeda) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the global revenues of Humira (adalimumab; Abbott/Eisai) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the global revenues of Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the global revenues of Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of Cimzia (certolizumab; UCB) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of Orencia (abatacept; Bristol-Myers Squibb) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of Actemra (tocilizumab) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of tofacitinib (CP-690,550; Pfizer/Takeda) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals) in Rheumatoid Arthritis, 2011–2016
Expected key impacting factors on the revenues of secukinumab (AIN457; Novartis) in Rheumatoid Arthritis, 2014–2016
